申请人:Synthelabo
公开号:US05453430A1
公开(公告)日:1995-09-26
Compounds of formula (I) ##STR1## wherein R represents a ##STR2## group in which R.sub.2 is a hydrogen atom, a (C.sub.1 -C.sub.4)alkoxycarbonyl group, a carboxylic group, a sodium carboxylate group, a --CH.sub.2 OR.sub.4 group R.sub.4 being a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group or a (C.sub.1 -C.sub.4)acyl group, an amide group of the formula --CONR.sub.5 R.sub.6, or a --CN.sub.4 R.sub.5 group, R.sub.5 being a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group and R.sub.6 being a hydrogen atom, a (C.sub.1 -C.sub.4)alkyl group, a hydroxy group or a (C.sub.1 -C.sub.4)alkoxy group, and R.sub.3 is a (C.sub.1 -C.sub.4)alkyl group, R.sub.1 represents either a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group, X represents either a sulphur atom, an oxygen atom or a methylene group, n=1 or 2 and Ar represents either a naphthalen-1-yl group substituted by a di(C.sub.1 -C.sub.4)alkylamino group, or a 6,7-di(C.sub.1 -C.sub.4)alkoxynaphthalen-1-yl group, or a quinolin-8-yl group substituted at 3 by a (C.sub.1 -C.sub.4)alkyl group, or a 1,2,3,4-tetrahydroquinolin-8-yl group substituted at 3 by a (C.sub.1 -C.sub.4)alkyl, or a 1H-indazol-7-yl group and pharmaceutically acceptable organic or inorganic salts thereof. Application in therapy.
化合物的化学式(I)##STR1##其中R代表一个##STR2##基团,其中R.sub.2是氢原子,(C.sub.1-C.sub.4)烷氧羰基基团,羧基,钠羧酸盐基团,--CH.sub.2 OR.sub.4基团,其中R.sub.4是氢原子或(C.sub.1-C.sub.4)烷基或(C.sub.1-C.sub.4)酰基,一种式为--CONR.sub.5R.sub.6的酰胺基团,或一种--CN.sub.4R.sub.5基团,其中R.sub.5是氢原子或(C.sub.1-C.sub.4)烷基,R.sub.6是氢原子,(C.sub.1-C.sub.4)烷基,羟基或(C.sub.1-C.sub.4)烷氧基,R.sub.3是(C.sub.1-C.sub.4)烷基,R.sub.1代表氢原子或(C.sub.1-C.sub.4)烷基,X代表硫原子,氧原子或亚甲基基团,n=1或2,Ar代表萘基,其被二(C.sub.1-C.sub.4)烷基氨基基团取代,或6,7-二(C.sub.1-C.sub.4)烷氧基萘基,或在3位被(C.sub.1-C.sub.4)烷基取代的喹啉-8-基团,或在3位被(C.sub.1-C.sub.4)烷基取代的1,2,3,4-四氢喹啉-8-基团,或1H-吲唑-7-基团,以及其药学上可接受的有机或无机盐。应用于治疗。